In the US, Rivaroxaban (rivaroxaban systemic) is a member of the drug class factor Xa inhibitors and is used to treat Atrial Fibrillation, Deep Vein Thrombosis, Deep Vein Thrombosis Prophylaxis after Hip Replacement Surgery, Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery, Deep Vein Thrombosis - Prophylaxis, Deep Vein Thrombosis - Recurrent Event, Prevention of Thromboembolism in Atrial Fibrillation, Pulmonary Embolism and Pulmonary Embolism - Recurrent Event.
- RIVAROXABAN SANDOZ 10 MG FILM-COATED TABLETS (Leaflet)
- RIVAROXABAN SANDOZ 15 MG FILM-COATED TABLETS (Leaflet)
- RIVAROXABAN SANDOZ 20 MG FILM-COATED TABLETS (Leaflet)
ATC (Anatomical Therapeutic Chemical Classification)
CAS registry number (Chemical Abstracts Service)
Anticoagulant agent: Direct, selective inhibitor of blood-coagulation factor Xa
- Rivaroxabanum (Latin)
- Rivaroxaban (German)
- Rivaroxaban (French)
- Rivaroxabán (Spanish)
- Rivaroxaban (OS: JAN, USAN, BAN)
- BAY 59-7939 (IS)
- UNII-9NDF7JZ4M3 (IS)
Bayer, Bosnia & Herzegowina; Bayer, Belgium; Bayer, Canada; Bayer, Chile; Bayer, China; Bayer, Colombia; Bayer, Costa Rica; Bayer, Czech Republic; Bayer, Denmark; Bayer, Dominican Republic; Bayer, Ecuador; Bayer, Egypt; Bayer, Spain; Bayer, United Kingdom; Bayer, Georgia; Bayer, Greece; Bayer, Guatemala; Bayer, Hong Kong; Bayer, Honduras; Bayer, Croatia (Hrvatska); Bayer, Haiti; Bayer, Hungary; Bayer, Ireland; Bayer, Italy; Bayer, South Korea; Bayer, Lebanon; Bayer, Latvia; Bayer, Nicaragua; Bayer, Netherlands; Bayer, New Zealand; Bayer, Panama; Bayer, Peru; Bayer, Philippines; Bayer, Poland; Bayer, Portugal; Bayer, Sweden; Bayer, Slovakia; Bayer, El Salvador; Bayer, Turkey; Bayer, Vietnam; Bayer de México, Mexico; Bayer Health Care, Malaysia; Bayer HealthCare, Finland; Bayer HealthCare, Russian Federation; Bayer HealthCare, Singapore; Bayer Pharma, Austria; Bayer Pharma, Israel; Bayer Pharma AG, Norway; Bayer Santé, France; Bayer Schering, Australia; Bayer Schering, Lithuania; Bayer Schering, Serbia; Bayer Schering, Tunisia; Bayer Schering, South Africa; Bayer Thai Co Ltd, Thailand; Bayer Vital, Germany; Bayer Yakuhin, Japan; Bayer-Schering, Iceland; Bayer-Schering, Romania; Janssen Pharma, United States; Mediwin, France
|BAN||British Approved Name|
|IUPAC||International Union of Pure and Applied Chemistry|
|JAN||Japanese Accepted Name|
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
|USAN||United States Adopted Name|
|WHO||World Health Organization|
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.